PTGXProtagonist Therapeutics, Inc.
Is the price fair?
A demanding price: priced for a lot of growth and rich vs its sector.
Priced for ~22% a year FCF growth. The price already bakes in strong, sustained growth.
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PTGX's price assumes
Protagonist Therapeutics, Inc. trades at 136× earnings against 19.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 19.8 · 6.86× the median: the market pays up for this one
- Price / sales
- 31.8
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 1.5%
Free cash flow yield · Biotechnology median 4.3%
- Growth the price implies
- +22%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 10.6
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 144
- EV / salestoday's price, trailing year to Jun 30, 2026
- 29.8
- Healthcare median P/E503 names
- 27.9
- Biotechnology median P/E242 names
- 19.8
- Free cash flow, trailing twelve months
- $131M
- Market capitalisation64.7 million shares, counted Jul 31, 2026
- $8.96B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.